Lamivudine(LAM) Good Responder Study

NCT01128686 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2016-09-13

No results posted yet for this study

Summary

This is to evaluate the proportion of subjects who show good responses to LAM treatment in Korea.

Conditions

  • Hepatitis B, Chronic

Interventions

OTHER

No intervention

This study is retrospective chart review

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · ViiV Healthcare

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • South Korea

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01128686 on ClinicalTrials.gov